Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1984 Jul;57(1):139–148.

Paradoxical presence of T cell anergy during successful T cell-dependent tumour immunotherapy: characterization of a state of T cell 'amnaesia' following systemic administration of C. parvum.

W H McBride, S Howie
PMCID: PMC1536085  PMID: 6235074

Abstract

Systemic administration of Corynebacterium parvum causes T cell-dependent regression of an established methylcholanthrene-induced murine fibrosarcoma beginning 10 days after Cp injection. At this time, tumour specific effector T cell responses measured by reactivity in a T helper cell assay or in a Winn assay disappear only to return later. We refer to this temporary lapse in T cell reactivity as immunological 'amnaesia'. Antigen specific T cell responses within all lymphoid organs appear to be affected. The 'amnaesic' state is characterised by the presence of primed T cells but the absence of T effector cells and suppressor cells. The differentiation of the primed T cells is blocked probably as a result on the non-delivery of a differentiation signal. There are several possible mechanisms which could account for this; the one we prefer is that cells are prevented from entering T cell-dependent cell interaction areas within lymphoid organs. This state of T cell 'amnaesia' may underlie anergy in some inflammatory, infectious and neoplastic diseases. The apparent paradox of T cell-dependent tumour regression occurring in mice with depressed T cell responses is discussed.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bullock W. E. Anergy and infection. Adv Intern Med. 1976;21:149–173. [PubMed] [Google Scholar]
  2. Castro J. E. The effect of Corynebacterium parvum on the structure and function of the lymphoid system in mice. Eur J Cancer. 1974 Feb;10(2):115–120. doi: 10.1016/0014-2964(74)90062-0. [DOI] [PubMed] [Google Scholar]
  3. Gidlund M., Orn A., Wigzell H., Senik A., Gresser I. Enhanced NK cell activity in mice injected with interferon and interferon inducers. Nature. 1978 Jun 29;273(5665):759–761. doi: 10.1038/273759a0. [DOI] [PubMed] [Google Scholar]
  4. Greager J. A., Baldwin R. W. Influence of immunotherapeutic agents on the progression of spontaneously arising, metastasizing rat mammary adenocarcinomas of varying immunogenicities. Cancer Res. 1978 Jan;38(1):69–73. [PubMed] [Google Scholar]
  5. Günther J., Haas W., Von Boehmer H. Suppression of T cell responses through competition for T cell growth factor (interleukin 2). Eur J Immunol. 1982 Mar;12(3):247–249. doi: 10.1002/eji.1830120315. [DOI] [PubMed] [Google Scholar]
  6. Howie S., McBride W. H., James K. Distribution of IgM, IgA and IgG secreting cells in the tissues of normal and tumour-bearing mice. Immunology. 1982 May;46(1):43–48. [PMC free article] [PubMed] [Google Scholar]
  7. Howie S., McBride W. H. Tumor-specific T helper activity can be abrogated by two distinct suppressor cell mechanisms. Eur J Immunol. 1982 Aug;12(8):671–675. doi: 10.1002/eji.1830120809. [DOI] [PubMed] [Google Scholar]
  8. James K., Woodruff M. F., McBride W. H., Willmott N. Serological changes associated with C. parvum treatment in nude mice. Br J Cancer. 1977 May;35(5):684–686. doi: 10.1038/bjc.1977.104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Julius M. H., Simpson E., Herzenberg L. A. A rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur J Immunol. 1973 Oct;3(10):645–649. doi: 10.1002/eji.1830031011. [DOI] [PubMed] [Google Scholar]
  10. Keller R. Abrogation of antitumor effects of Corynebacterium parvum and BCG by antimacrophage agents: brief communication. J Natl Cancer Inst. 1977 Dec;59(6):1751–1753. doi: 10.1093/jnci/59.6.1751. [DOI] [PubMed] [Google Scholar]
  11. Kirchner H., Holden H. T., Herberman Splenic suppressor macrophages induced in mice by injection of Corynebacterium parvum. J Immunol. 1975 Nov;115(5):1212–1216. [PubMed] [Google Scholar]
  12. Kumar V., Luevano E., Bennett M. Hybrid resistance to EL-4 lymphoma cells. I. Characterization of natural killer cells that lyse EL-4 cells and their distinction from marrow-dependent natural killer cells. J Exp Med. 1979 Sep 19;150(3):531–547. doi: 10.1084/jem.150.3.531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. McBride W. H., Dawes J., Dunbar N., Ghaffar A., Woodruff M. F. A comparative study of anaerobic Coryneforms. Attempts to correlate their anti-tumour activity with their serological properties and ability to stimulate the lymphoreticular system. Immunology. 1975 Jan;28(1):49–58. [PMC free article] [PubMed] [Google Scholar]
  14. Milas L., Hunter N., Basić I., Withers H. R. Complete regressions of an established murine fibrosarcoma induced by systemic application of Corynebacterium granulosum. Cancer Res. 1974 Oct;34(10):2470–2475. [PubMed] [Google Scholar]
  15. Milas L., Kogelnik H. D., Basic I., Mason K., Hunter N., Withers H. R. Combination of C. parvum and specific immunization against artificial pulmonary metastases in mice. Int J Cancer. 1975 Nov 15;16(5):738–746. doi: 10.1002/ijc.2910160506. [DOI] [PubMed] [Google Scholar]
  16. Moore K., McBride W. H. Enhanced Fc receptor expression by a sub-population of murine intra-tumour macrophages following intravenous Corynebacterium parvum therapy. Br J Cancer. 1983 Jun;47(6):797–802. doi: 10.1038/bjc.1983.133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Moore K., McBride W. H. The activation state of macrophage subpopulations from a murine fibrosarcoma. Int J Cancer. 1980 Nov 15;26(5):609–615. doi: 10.1002/ijc.2910260513. [DOI] [PubMed] [Google Scholar]
  18. Peters L. J., McBride W. H., Mason K. A., Milas L. A role for T lymphocytes in tumour inhibition and enhancement caused by systemic administration of Corynebacterium parvum. J Reticuloendothel Soc. 1978 Jul;24(1):9–18. [PubMed] [Google Scholar]
  19. Scott M. T. Corynebacterium parvum as a therapeutic antitumor agent in mice. I. Systemic effects from intravenous injection. J Natl Cancer Inst. 1974 Sep;53(3):855–860. doi: 10.1093/jnci/53.3.855. [DOI] [PubMed] [Google Scholar]
  20. Scott M. T. Corynebacterium parvum as a therapeutic antitumor agent in mice. II. Local injection. J Natl Cancer Inst. 1974 Sep;53(3):861–865. doi: 10.1093/jnci/53.3.861. [DOI] [PubMed] [Google Scholar]
  21. Toujas L., Dazord L., Martin A., Guelfi J. Simultaneous stimulation of plaque forming cells and depression of cellular immunity to sheep erythrocytes, after adjuvant treatment. Biomedicine. 1973 Nov 20;19(11):503–505. [PubMed] [Google Scholar]
  22. Watson J., Gillis S., Marbrook J., Mochizuki D., Smith K. A. Biochemical and biological characterization of lymphocyte regulatory molecules. I. Purification of a class of murine lymphokines. J Exp Med. 1979 Oct 1;150(4):849–861. doi: 10.1084/jem.150.4.849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Woodruff M., Dunbar N., Ghaffar A. The growth of tumours in T-cell deprived mice and their response to treatment with Corynebacterium parvum. Proc R Soc Lond B Biol Sci. 1973 Aug 31;184(1074):97–102. doi: 10.1098/rspb.1973.0034. [DOI] [PubMed] [Google Scholar]
  24. Zola H. Mitogenicity of Corynebacterium parvum for mouse lymphocytes. Clin Exp Immunol. 1975 Dec;22(3):514–521. [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES